Genomics of Pulmonary Arterial Hypertension

Implications for Therapy

Mark W. Geraci, Todd M. Bull, Rubin M. Tuder

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Pulmonary arterial hypertension (PAH) remains a vexing clinical disease with no cure. Despite advances and the discovery of a gene (BMPR2) associated with many of the hereditary forms of the disease, and some cases not previously known to be inherited, the reasons for mutations in this gene as a cause remain somewhat elusive. Clearly, a complex interplay exists between genetic alterations, environmental exposures (including infections), and disease development. This article addresses the advances in the genetics of PAH, including the identification of genetic etiologies and modulators, and the role of genetics in predicting disease progression and targeting therapeutics.

Original languageEnglish (US)
Pages (from-to)101-114
Number of pages14
JournalHeart Failure Clinics
Volume6
Issue number1
DOIs
StatePublished - Jan 2010
Externally publishedYes

Fingerprint

Genomics
Pulmonary Hypertension
Inborn Genetic Diseases
Environmental Exposure
Genetic Association Studies
Disease Progression
Mutation
Therapeutics
Infection
Genes

Keywords

  • Gene expression
  • Genetics
  • Genomics
  • Microarray
  • Pulmonary hypertension

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Genomics of Pulmonary Arterial Hypertension : Implications for Therapy. / Geraci, Mark W.; Bull, Todd M.; Tuder, Rubin M.

In: Heart Failure Clinics, Vol. 6, No. 1, 01.2010, p. 101-114.

Research output: Contribution to journalArticle

Geraci, Mark W. ; Bull, Todd M. ; Tuder, Rubin M. / Genomics of Pulmonary Arterial Hypertension : Implications for Therapy. In: Heart Failure Clinics. 2010 ; Vol. 6, No. 1. pp. 101-114.
@article{ac812fa9f1d5417b9d6db783655ee72f,
title = "Genomics of Pulmonary Arterial Hypertension: Implications for Therapy",
abstract = "Pulmonary arterial hypertension (PAH) remains a vexing clinical disease with no cure. Despite advances and the discovery of a gene (BMPR2) associated with many of the hereditary forms of the disease, and some cases not previously known to be inherited, the reasons for mutations in this gene as a cause remain somewhat elusive. Clearly, a complex interplay exists between genetic alterations, environmental exposures (including infections), and disease development. This article addresses the advances in the genetics of PAH, including the identification of genetic etiologies and modulators, and the role of genetics in predicting disease progression and targeting therapeutics.",
keywords = "Gene expression, Genetics, Genomics, Microarray, Pulmonary hypertension",
author = "Geraci, {Mark W.} and Bull, {Todd M.} and Tuder, {Rubin M.}",
year = "2010",
month = "1",
doi = "10.1016/j.hfc.2009.08.001",
language = "English (US)",
volume = "6",
pages = "101--114",
journal = "Heart Failure Clinics",
issn = "1551-7136",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Genomics of Pulmonary Arterial Hypertension

T2 - Implications for Therapy

AU - Geraci, Mark W.

AU - Bull, Todd M.

AU - Tuder, Rubin M.

PY - 2010/1

Y1 - 2010/1

N2 - Pulmonary arterial hypertension (PAH) remains a vexing clinical disease with no cure. Despite advances and the discovery of a gene (BMPR2) associated with many of the hereditary forms of the disease, and some cases not previously known to be inherited, the reasons for mutations in this gene as a cause remain somewhat elusive. Clearly, a complex interplay exists between genetic alterations, environmental exposures (including infections), and disease development. This article addresses the advances in the genetics of PAH, including the identification of genetic etiologies and modulators, and the role of genetics in predicting disease progression and targeting therapeutics.

AB - Pulmonary arterial hypertension (PAH) remains a vexing clinical disease with no cure. Despite advances and the discovery of a gene (BMPR2) associated with many of the hereditary forms of the disease, and some cases not previously known to be inherited, the reasons for mutations in this gene as a cause remain somewhat elusive. Clearly, a complex interplay exists between genetic alterations, environmental exposures (including infections), and disease development. This article addresses the advances in the genetics of PAH, including the identification of genetic etiologies and modulators, and the role of genetics in predicting disease progression and targeting therapeutics.

KW - Gene expression

KW - Genetics

KW - Genomics

KW - Microarray

KW - Pulmonary hypertension

UR - http://www.scopus.com/inward/record.url?scp=70450230547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70450230547&partnerID=8YFLogxK

U2 - 10.1016/j.hfc.2009.08.001

DO - 10.1016/j.hfc.2009.08.001

M3 - Article

VL - 6

SP - 101

EP - 114

JO - Heart Failure Clinics

JF - Heart Failure Clinics

SN - 1551-7136

IS - 1

ER -